Alnylam Reports Positive Initial Phase 1b Data for Brezosiran
Alnylam reported positive initial Phase 1b results for ALN-HTT02, an investigational RNAi therapy for Huntington’s disease, demonstrating deep and durable huntingtin lowering.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, which will be developed under the Internat…